PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification

NCT05049837 · M.D. Anderson Cancer Center

Recruiting

In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study

Objectives: 1. To develop a therapeutic target -focused (TTF) profiling platform and to use it in vitro to identify potential therapeutic targets associated with therapeutic resistance and to develop novel approaches against these potential targets. 2. To use tumor tissue TTF profiling along with genome wide mRNA profiling, serum phosphopeptide profiling and plasma DNA profiling to identify and evaluate molecular targets and pathways that contribute to therapeutic sensitivity or resistance, prognosis, and recurrence patterns in patients with operable non-small cell lung carcinoma (NSCLC).

Eligibility criteria

Inclusion Criteria: Eligible patients should be ones who have stage I-IIIA non-small cell lung cancer (NSCLC) and undergo surgical resection with or without neoadjuvant chemotherapy as part of standard treatment, and have a information of demographics, smoking history, preoperative clinical data, and follow -up data including adjuvant therapy, relapse, and treatment at relapse. We will include the three major NSCLC histologic subtypes, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma - Exclusion Criteria: None

Study design

Enrollment target: 7200 participants

Age groups: adult, older_adult

Timeline

Starts: 2007-04-25

Estimated completion: 2025-12-31

Last updated: 2025-08-15

Interventions

Other: Group Specific Aim 1Other: Group Specific Aim 2Other: Group Specific Aim 3Other: Group Specific Aim 4Other: Group Specific Aim 5Other: Group Specific Aim 6

Primary outcomes

• To develop a therapeutic target -focused (TTF) profiling platform and to use it in vitro to identify potential therapeutic targets associated with therapeutic resistance and to develop novel approaches against these potential targets. (through study completion, an average of 1 year)

Sponsor

M.D. Anderson Cancer Center · other

With: United States Department of Defense, National Institutes of Health (NIH), National Cancer Institute (NCI)

Contacts & investigators

ContactLuisa M Solis Soto, MD · contact · lmsolis@mdanderson.org · 832-794-1469

InvestigatorLuisa M Solis Soto, MD · principal_investigator, M.D. Anderson Cancer Center

All locations (1)

M D Anderson Caner CenterRecruiting

Houston, Texas, United States

View on ClinicalTrials.gov ↗Find similar trials